​Sanofi (NASDAQ:SNY) is one of the Cheap NASDAQ Stocks to Buy Now. On December 4, Sanofi (NASDAQ:SNY) announced the completion of the Vicebio acquisition. Vicebio is a clinical-stage biotechnology company focused on developing transformative multi-pathogen vaccines for respiratory viral infections. ​Management noted that this strategic acquisition brings Vicebio’s early-stage vaccine candidate for respiratory syncytial virus and human metapneumovirus under Sanofi’s portfolio. Moreover, the company also no ...

​Sanofi (NASDAQ:SNY) is one of the Cheap NASDAQ Stocks to Buy Now. On December 4, Sanofi (NASDAQ:SNY) announced the completion of the Vicebio acquisition. Vicebio is a clinical-stage biotechnology company focused on developing transformative multi-pathogen vaccines for respiratory viral infections. ​Management noted that this strategic acquisition brings Vicebio’s early-stage vaccine candidate for respiratory syncytial virus and human metapneumovirus under Sanofi’s portfolio. Moreover, the company also no ...

Kymera Therapeutics (NasdaqGM:KYMR) Update / Briefing December 08, 2025 08:00 AM ET Company ParticipantsJustine Koenigsberg - Head of Investor RelationsGeoff Meacham - Global Head of HealthcareMayank Mamtani - Group Head of Healthcare ResearchJared Gollob - Chief Medical OfficerBruce Jacobs - CFONello Mainolfi - Founder, President, and CEOConference Call ParticipantsAndrea Newkirk - Equity AnalystJeet Mukherjee - VP and Biotechnology AnalystBrian Cheng - Senior Biotech AnalystSudan Loganathan - Biotechnolog ...

Core Viewpoint - The article discusses the market outlook for 2026, emphasizing a potential for lower interest rates due to a softer labor market, which could positively impact stock market performance [2][3][4]. Market Outlook - Michael Kantrowitz, Chief Investment Strategist at Piper Sandler, believes the stock market is set for a strong performance heading into 2026, with a focus on historical context to understand current market dynamics [2]. - The current labor market conditions are seen as a new concern, but they may lead to lower interest rates, which historically correlate with improved stock market performance [3]. Interest Rates and Market Dynamics - Higher interest rates have been a barrier to market broadening, but a shift to lower rates could benefit underperforming sectors such as manufacturing, transportation, and housing in 2026 [4]. Investment Opportunities - The article lists 12 cheap NASDAQ stocks to consider for investment, identified through a methodology that includes screening for stocks with a forward price-to-earnings ratio below 15 and cross-referencing hedge fund interest [7][8]. Company Highlights - **Sanofi (NASDAQ:SNY)**: - Forward P/E Ratio: 10.7, with 32 hedge fund holders. Recently completed the acquisition of Vicebio, enhancing its vaccine development capabilities [9][10][11]. - Received EU approval for Dupilumab, a treatment for chronic spontaneous urticaria, expanding its market potential significantly [12][13]. - **Trip.com Group Limited (NASDAQ:TCOM)**: - Forward P/E Ratio: 11.01, with 37 hedge fund holders. Reported a 17.64% year-over-year revenue growth to $2.58 billion in fiscal Q3 2025, exceeding estimates [14][16]. - Strong performance driven by cross-border travel, with international bookings increasing by 60% year-over-year and inbound travel bookings more than doubling [16][17].

Summary of AnaptysBio Conference Call Company Overview - **Company**: AnaptysBio (NasdaqGS:ANAB) - **Focus**: Development of biologics or antibodies for autoimmune diseases - **Clinical Programs**: Three clinical stage programs including Rosnilimab, AMV033, and AMV101 [1][2] Key Clinical Programs Rosnilimab - **Type**: Selective and potent depleter of pathogenic T cells - **Recent Development**: Positive phase 2b trial readout in arthritis with plans to advance into phase 3 trials for rheumatoid arthritis (RA) [1][24] - **Trial Details**: Robust study with 424 patients, showing high tolerability and sustained responses off-drug [24][30] AMV033 - **Type**: CD122 antagonist blocking IL-15 and IL-2 signaling - **Current Status**: Phase 1b trial initiated for celiac disease, with plans for a second indication in 2026 [1][2][7] - **Mechanism**: Designed to target autoimmune cells, particularly CD8 T cells in diseases like celiac disease and eosinophilic esophagitis (EOE) [8][20] AMV101 - **Current Status**: In phase 1a trials with results expected next year [1][32] Royalty Management Business - **Separation Announcement**: Company plans to separate into two businesses: biopharma operations and royalty management [2] - **Key Products**: - **Jemperli**: PD-1 antagonist with expected run rate of $1.4 billion to $1.5 billion; AnaptysBio anticipates substantial royalties based on sales tiers [3][4] - **Imsidolimab**: IL-36 receptor antagonist partnered with Vanda Pharmaceuticals, expected approval next year [6] Financial Overview - **Cash Position**: Expected $300 million cash at the end of the year [2] - **Royalty Structure**: Royalties range from 8% to 25% based on sales thresholds, with potential for significant revenue [4][6] Market Opportunity - **Celiac Disease**: Estimated 2 million patients in the US, with 250,000 potentially eligible for biologics by the 2030s [19] - **EOE Market**: Dupilumab, the only approved therapy, has generated $2 billion in sales, indicating a growing market for new therapies [20][23] Competitive Landscape - **Competitors**: Other companies like Novartis and Teva are also developing therapies targeting similar pathways in autoimmune diseases [9][10] - **Differentiation**: AnaptysBio's approach targets both inflammation and the underlying autoimmune response, which may provide advantages over existing therapies [15][22] Conclusion - **Future Plans**: AnaptysBio aims to advance AMV033 into further trials and move Rosnilimab into phase 3 next year, with a focus on addressing significant unmet needs in autoimmune diseases [31][32]

Financial Data and Key Metrics Changes - Revenue for Q3 2025 was $2.8 million, entirely from collaboration with Gilead [24] - R&D expenses were $74.1 million, with adjusted cash R&D spend of $65.7 million, reflecting a 7% decrease from Q2 2025 [24] - G&A expenses totaled $17.3 million, with adjusted cash G&A spend of $9.9 million, a 3% decrease from Q2 2025 [24] - Cash balance at the end of September was $978.7 million, providing a runway into the second half of 2028 [25] Business Line Data and Key Metrics Changes - The company has made significant progress in its STAT6 program, with the first-in-class STAT6 degrader, KT-621, advancing through clinical trials [5][6] - The Broaden-2 phase 2b trial for atopic dermatitis has been initiated, evaluating three different doses of KT-621 [20] - The company is also advancing its IRF5 program, with plans to initiate a phase 1 study in early 2026 [22] Market Data and Key Metrics Changes - The company is targeting a significant unmet need in the oral immunology market, particularly for type 2 diseases like atopic dermatitis and asthma [8][16] - The penetration of advanced therapies like injectable biologics in moderate to severe patients is less than 10%, indicating a substantial market opportunity for oral therapies [56] Company Strategy and Development Direction - The company has shifted its R&D focus towards immunology, aiming to develop oral medicines with biologics-like activity [7] - The strategic partnership with Gilead aims to advance the CDK2 oncology molecular glue program, expanding the company's portfolio beyond immunology [6] - The company is committed to building a fully integrated commercial-stage company, with a focus on advancing its pipeline towards important milestones [15] Management's Comments on Operating Environment and Future Outlook - Management expressed confidence in the execution of their strategy and the potential of their oral immunology pipeline to address significant patient needs [4][15] - The company anticipates strong interest in oral medicines with biologics-like activity, as evidenced by recent presentations and data [5][6] - Management highlighted the importance of continuous pathway blockade offered by KT-621 compared to injectable biologics, which may have less consistent effects [67] Other Important Information - The company has completed IND-enabling studies for KT-579 and plans to advance it into clinical trials in early 2026 [22] - The company expects to receive milestone payments from collaborations with Sanofi and Gilead as their partnered programs progress [25] Q&A Session Summary Question: Key characteristics that could enable KT-621 to show differential efficacy versus Dupilumab - Management highlighted that KT-621 has demonstrated comparable activity to Dupilumab in preclinical studies, blocking IL-4 and IL-13 signaling effectively [29][30] Question: Expectations regarding the doses in the Broaden study - Management explained that the selected doses aim to understand the translation of healthy volunteer data into patients, ensuring confidence in the phase 2b dose selection [32] Question: Concerns about baseline characteristics of enrolled patients - Management clarified that baseline levels of TARC and EASI scores are important factors, and they will share data when appropriate [39] Question: Powering for the phase 2b AD study - Management stated that the study is designed to be adequately powered to show desired effects relative to placebo, with careful consideration of patient enrollment [45] Question: Competitive landscape for KT-621 - Management emphasized that being first and best is crucial for commercial success, and they believe KT-621's profile will be difficult for competitors to surpass [79]

Financial Data and Key Metrics Changes - The company reported $430 million in cash at the end of the last quarter, which is expected to sustain operations through 2027, covering key milestones such as nasal polyps and severe asthma readouts [73][74]. Business Line Data and Key Metrics Changes - The company is developing Virecitug, a monoclonal antibody targeting the receptor for TSLP, which is unique in the market as it is the only drug in development targeting the receptor rather than the ligand [3][13]. - Clinical trials indicate that Virecitug can be dosed every 12 or 24 weeks, potentially offering a differentiated dosing schedule compared to competitors [4][19]. Market Data and Key Metrics Changes - The competitive landscape includes established products like tezepelumab, which targets the TSLP ligand, and the company believes that targeting the receptor may provide superior efficacy and broader patient eligibility [9][12][36]. Company Strategy and Development Direction - The company aims to differentiate itself through the unique pharmacology of Virecitug, which shows significant effects on disease-driving biomarkers like exhaled nitric oxide and blood eosinophils [13][25]. - The strategic focus includes exploring the potential for Virecitug in chronic rhinosinusitis and COPD, with plans to design trials that could demonstrate efficacy in these areas [71][72]. Management's Comments on Operating Environment and Future Outlook - Management expressed confidence in the safety profile of TSLP signaling, drawing parallels with the clean label of tezepelumab, and anticipates a similar profile for Virecitug [23][38]. - The company is actively preparing for commercial considerations and market access strategies as it progresses through clinical development [75][76]. Other Important Information - The company has completed enrollment in its nasal polyp study and expects to release data in Q3 of this year, with a robust trial design aimed at regulatory approval [49][50]. - The company is considering both in-office and at-home administration options for Virecitug, aligning with patient visit schedules [45][46]. Q&A Session Summary Question: Can you clarify the dosing intervals and their implications? - The company explained that the receptor is expressed at a low level compared to the circulating ligand, allowing for extended dosing intervals without significant risks [20][21]. Question: How does the company view the competitive landscape with other agents? - Management noted that while there are various agents in development, the efficacy and breadth of eligibility will drive prescribing behaviors, with a focus on the convenience of dosing intervals [33][37]. Question: What is the company's cash runway and future funding plans? - The company confirmed a strong cash position that supports its current and future clinical programs, although additional funds will be needed over time [73][74].

KT-621 Phase 1 Healthy Volunteer Trial Results - KT-621 demonstrated >90% STAT6 degradation in blood at doses above 1.5 mg [58, 112] - Complete STAT6 degradation was achieved in both blood and skin at doses ≥5 mg [58, 81, 87, 112] - KT-621 showed a favorable PK profile with rapid absorption (tmax of 2-4 hours) and a mean half-life of 9-36 hours [73] - The Phase 1 trial included 118 healthy volunteers in SAD and MAD groups [65] Th2 Biomarker Impact - KT-621 achieved up to 37% median TARC reduction [98] - KT-621 achieved up to 63% median Eotaxin-3 reduction [104] - IgE levels showed high variability and minimal changes, consistent with dupilumab effects in healthy volunteers [101, 103] Safety and Tolerability - KT-621 was well-tolerated with a safety profile undifferentiated from placebo [58, 107, 112] - No SAEs or severe AEs were reported in the healthy volunteer trial [108] Future Development - The company plans to initiate Phase 2b trials in Atopic Dermatitis (AD) and Asthma, starting in Q4 2025 and Q1 2026, respectively [21, 50] - The company has $775 million in cash and expects the runway to last into the first half of 2028 [16]

Financial Data and Key Metrics Changes - Revenue for Q4 2024 was $7.4 million, entirely from the Sanofi collaboration [36] - R&D expenses for the quarter were $71.8 million, with adjusted cash R&D spend of $65 million reflecting a 23% sequential increase from Q3 [37] - G&A expenses were $16.3 million, with adjusted cash G&A spend of $9.3 million, up 13% sequentially [37] - Cash balance at the end of 2024 was $851 million, providing a runway into mid-2027 [38] Business Line Data and Key Metrics Changes - The company is focused on advancing its immunology pipeline, particularly with the STAT6 and TYK2 programs [8][12] - Progress in the STAT6 program includes completing IND-enabling studies for KT-621 and initiating a Phase I healthy volunteer study [9][10] - The TYK2 program is advancing with the development candidate KT-295, with plans to start a Phase I healthy volunteer study [11][30] Market Data and Key Metrics Changes - The company aims to develop therapies that provide biologic-like efficacy with the convenience of an oral daily pill, targeting a broad patient population [8][16] - The strategic focus on immunology is expected to expand access to millions of patients globally [8] Company Strategy and Development Direction - Kymera is committed to developing an industry-leading immunology pipeline featuring innovative oral small molecule therapies [16] - The goal is to deliver at least one new IND per year, with multiple clinical advancements expected in 2025 [15][34] - The company plans to unveil a new immunology target in May, which aligns with its pipeline strategy [34] Management's Comments on Operating Environment and Future Outlook - Management expressed confidence in the progress made in 2024 and the potential for a productive 2025 with several clinical advancements [12][34] - The company believes that its oral medicines can provide a differentiated solution compared to traditional small molecules and biologics [17] Other Important Information - The company is transitioning its quarterly financial updates to a video format to enhance transparency and communication with stakeholders [7] - A director, Leigh Morgan, will not stand for reelection at the upcoming Annual Shareholder Meeting [18] Q&A Session Summary Question: What supports your view that the 28 dosing in the atopic derm Phase Ib is enough time to show robust biomarker activity? - Management referenced prior dupilumab trials showing clear impacts on Th2 biomarkers at four weeks, indicating confidence in the 28-day study design [43][44] Question: Can you comment on the choice to not have a placebo arm in the Phase 1b? - Management believes that a placebo is unnecessary for demonstrating biomarker profiles, as biomarkers do not significantly change in placebo arms [49][50] Question: What do we know about the potential bioavailability of KT-621 in tissues of interest? - Preclinical data indicates that KT-621 is orally bioavailable and shows consistent degradation across various tissues, including skin and lungs [65][66] Question: How expansive of a Phase 3 development program would you expect to initiate for KT-621? - The company plans to run important Phase 2b studies to inform Phase 3 selection for potentially eight different indications, prioritizing asthma and atopic dermatitis [137][138]